Tefft M, Fernandez C H, Moon T E
Cancer. 1977 Feb;39(2):665-70. doi: 10.1002/1097-0142(197702)39:2<665::aid-cncr2820390244>3.0.co;2-b.
One hundred and ten Group III patients enrolled in the IRS Study have been reviewed. Of these, 39 are fully and 56 are partially evaluable. Combining the data for both groups 77/95 (81%) have shown complete or partial response/no measurable disease and this has been maintained in 53/95 (56%). No patient received premature RT for local progression during the time of pre-radiation chemotherapy. However, 15/95 patients have shown local recurrence or direct extension to neighboring tissues; 13/15 could be reviewed. Only 3/13 have recurred at a time related to the delay in starting radiation. Overall survival for Group III patients is 72%-85% (Regimen F and Regimen E respectively).
对纳入IRS研究的110例Ⅲ组患者进行了回顾。其中，39例可完全评估，56例可部分评估。将两组数据合并后，77/95（81%）的患者显示出完全或部分缓解/无可测量疾病，并且53/95（56%）的患者维持了这一状态。在放疗前化疗期间，没有患者因局部进展而接受过早放疗。然而，15/95的患者出现了局部复发或直接蔓延至邻近组织；13/15的患者可以进行复查。只有3/13的患者在与开始放疗延迟相关的时间出现复发。Ⅲ组患者的总生存率分别为72% - 85%（分别为方案F和方案E）。
